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Abstract 
Introduction: Insomnia is one of the most common health conditions amongst the elderly population.  It causes suffering 
and numerous health problems for those affected. 
Objectives: To review published results of common non-pharmacological and pharmacological interventions of insomnia 
and to discuss their application in older patient groups.  
Methods: We conducted a systematic literature review for the topic non-pharmacological treatment of Insomnia in Elderly 
and non-systematic review on the topic of pharmacological treatment using the electronic databases PubMed, PsycInfo, 
Google Scholar and Web of Knowledge. Only published articles and reviews were included.  
Results:  Sleep education can support the onset of sleep. As a simple and side-effect-free measure, sleep education should be 
offered to all elderly individuals with sleep-onset insomnia including those living in retirement homes. Stimulus control 
means that the bed or the bedroom should only be visited, if there is sufficient tiredness, or left, when tiredness is not suffi-
cient, which is very challenging and sometimes impossible due to the decreasing mobility of the elderly, especially under 
treatment with hypnotics. Sleep restriction can be conducted in a moderate way, reducing the time spent in bed every week 
for 30 minutes. Light therapy supports the regulation of the circadian body rhythm by exposing the patients to bright artificial 
light during the day. As a simple measure with only a few side effects, it is suitable when treating elderly individuals in insti-
tutions. Digital therapies are an emerging trend in the treatment of sleep disorders and require further empirical investigation 
of their effectiveness in the treatment of insomnia in the elderly. Non-pharmacological therapy should be the first-line thera-
py according to guidelines. Prescribing of sleep medication should take into account the period of time until the maximum 
effective level is reached, the half-life of the preparation, the binding behaviour to receptors and the metabolism of the prepa-
ration, which is especially relevant for elderly populations due to polypharmacy.  
Conclusion and implications: A modified, short cognitive behavioural therapy for insomnia combined with light therapy is 
the treatment of choice for elderly patients. However, a short-term pharmacological therapy is recommended as a temporary 
solution to immediately reduce high levels of distress. It is suggested to integrate both therapeutic approaches into a compre-
hensive therapeutic concept for insomnia in elderly people. 
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Introduction 
In the general population insomnia is one of the 
most common health disorders. Studies show a 
prevalence of 12 to 40% (Roth et al., 2011). De-
pending on the sample population, the prevalence 
increases with age to 20 to 50% (Alessi & Vitiello, 
2015, Patel et al. 2018). The incidence of insomnia 
in the elderly is reported to be about 5% (Geiger et 
al., 2015). Insomnia is characterised by difficulties 
falling asleep, sleeping through or waking up early 
on most days of the week for at least a month, 
AASM, 2014). 
Even at an advanced age, insomnia causes fatigue, 
drowsiness, impaired attention as well as cognitive 
and functional impairments (Bloom et al., 2009) to 
an extent that varies from individual to individual. 
Moreover, insomnia in the elderly is an independ-
ent risk factor for falling (Stone, Ensrud & Ancoli-
Israel, 2008). Insomnia is also often associated with 
other health problems in older people. Sleep dis-
turbances have been linked to increased morbidity 
and mortality and alteration of biomarkers for dia-
betes and cardiovascular disease risk (Caroll et al. 
2015). Especially in older women, habitual sleep 
duration predicts the future risk for cognitive im-
pairments including dementia, independent of 
vascular risk factors. (Chen 2015). 
Insomnia disorder can occur as a single or comor-
bid disease and the basic principles of treatment are 
the same (Riemann et al., 2017). 
This literature review aims to highlight different 
forms of insomnia treatment and their outcomes 
and the implications to consider when treating 
elderly persons with chronic insomnia.   
Methods  
For the non-pharmacological treatment of insom-
nia in elderly we conducted a systematic literature 
review using the electronic databases PubMed, 
PsycInfo, Google Scholar and Web of Knowledge. 
Studies were identified by the combination of the 
keywords: “insomnia”, “behavioural therapy”, 
“sleep”, “age”, “geriatrics” and “non-
pharmacological treatment”. We only included 
original research or reviewed articles from 2013 to 
2019.  
The total number of all identified studies was 
N=723. Research articles were discarded if the title 
and abstract were unrelated to the subject of this 
systematic review and further analysed when the 
articles were written in German or English.  Twen-
ty three of the identified articles met the inclusion 
criteria on title and abstract level. They were ob-
tained in full-text and analysed thoroughly.  Studies 
were further excluded either on the basis of date or 
if the focus on insomnia was insufficient, if there 
were confusions with pharmacological therapies or 
other age-related conditions such as dementia were 
present. In addition, the sample should foremost 
consist of older populations. The final number of 
reviewed publications that met the inclusion criteria 
on text-level is N=10.  
For the pharmacological treatment of insomnia we 
included some relevant papers without systematic 
literature research using the electronic databases 
PubMed, Google Scholar and Web of Knowledge. 
Studies were identified by the combination of the 
keywords “insomnia”, “behavioural therapy”, 
“hypnotics”, “light therapy” and “geriatrics”.  
Research articles were discarded if title and abstract 
were unrelated to the subject of this review and 
further analysed when the articles were written in 
German or English. The remaining articles were 
obtained in full-text and analysed thoroughly. Arti-
cles that fit the aforementioned inclusion criteria 
were included in the analysis.  
In view of the different ways of treating insomnia, 
also taking certain considerations into account 
when treating the older populations, this review 
was divided between pharmacological and non-
pharmacological approaches. 
Results 
Non-pharmacological treatment of insomnia 
The non-pharmacological therapy of insomnia 
(cognitive behavioural therapy for insomnia-CBT-
I) is evidence-based non-pharmacological therapy 
of insomnia in young and old populations (Rie-
mann et al. 2017, AASM 2014) and covers differ-
ent behavioural interventions. All of these non-
pharmacological therapy methods improve sleep 
(effect approx. 40%) and the nocturnal awake 
phases (effect approx. 50%). The total sleep time is 
less strongly influenced (increase of about 5%) 
(Geiger-Brown et al., 2015). These effects are also 
more pronounced than in the case of a sole phar-
macotherapy (Sivertsen et al., 2006). Many of these 
non-pharmacological therapies are used in combi-
nation.  
 
Medical Aspects of Disability 
________________________________________________________________________________  
Journal for ReAttach Therapy and Developmental Diversities 2020 Jan 22; 2(2):129-138                           131 
Sleep hygiene (Sleep education) 
Sleep hygiene or sleep education is the most basic 
and simplest behavioural therapeutic measure and 
can be applied to all sleep disorders and settings 
including clinics,  home care, protected homes or 
hospital settings (Stepanski and Wyatt, 2003). 
Sleep education includes behaviours that promote 
the onset of sleep. 
Sleep education measures include: 
• after lunch, do not drink caffeinated bev-
erages (coffee, black tea, cola) anymore 
• avoiding alcohol as far as possible and 
never use it as a sleeping aid. 
• no heavy meals in the evening 
• regular physical activity 
• gradual reduction of mental and physical 
arousal before going to bed 
• introduce a personal sleep ritual  
• do not stay in bed longer than necessary-
no longer than 30 minutes 
• provide a pleasant atmosphere in the bed-
room (quiet, darkened) 
• do not look at the alarm clock or the 
wristwatch at night 
• provide a quiet and well-tempered envi-
ronment 
• do not drink large amounts of water or tea 
at bedtime 
The daily routine should also be structured includ-
ing a consistent time for getting up and going to 
bed. Sleep disturbed people often have inconstant 
rhythms with considerable differences from day to 
day (Cheek, Shaver & Lentz, 2004). Elderly peo-
ple should not go too early to bed for sleeping, 
because getting into bed too early can lead to early 
awakening between 3 and 5 AM. 
Premature awakening in the early morning is the 
most prominent problem reported by the elderly 
regarding bad sleep quality.  
Particularly in facilities and hospitals, it should be 
ensured that patients/residents staying in multiple-
bed rooms do not interfere directly with each other 
during the night's rest by watching TV for long 
periods, listening to music, restlessness or snoring, 
and indirectly by the heightened need for care.  
However, a disregard for sleep hygiene is rarely the 
sole cause of disturbed sleep. It is therefore not 
surprising that studies show that sleep hygiene 
alone is often not sufficient to permanently im-
prove pronounced sleep disorders (Bloom et al., 
2009). 
Nevertheless, sleep hygiene or sleep education 
measures should be used as a simple and side-
effect-free basic measure for any form of sleep 
disorder in elderly people. 
Stimulus control  
Stimulus control is considered to be a very effective 
behavioural treatment method for insomnia. 
Through operant learning, the ability to fall asleep 
and to sleep through the night is promoted. 
Through stimulus control, the day-night rhythm is 
stabilised and the importance of the bed and the 
bedroom as a sleeping environment is strengthened 
(Morin et al., 2006). 
The bed should only be visited if tiredness is pre-
sent.  Tiredness indicates that the sleep pressure is 
sufficiently high. Going to bed without feeling tired 
leads to frustration, as sleep cannot be forced. 
If no sleep occurs about 20 minutes after going to 
bed, the person should get up out of bed. The dura-
tion of 20 minutes should be felt and not "checked" 
by looking at a clock. A watch should be posi-
tioned in the bedroom so that from the bed no di-
rect view of the dial is possible. After leaving the 
bed, it is important not to carry out any stimulating 
activities. The bed should not be visited again until 
there is drowsiness and immediate sleep can be 
expected. If no sleep occurs again, the bed is left 
again and this behavioural cycle is repeated.  
The time of getting up in the morning should be 
fixed and should be adhered to regardless of the 
amount of sleep achieved at night. 
This behaviour stabilises the circadian rhythm and 
sustainably improves sleep efficiency. 
Rules of stimulus control (Riemann et al., 2016) 
- The bed is only used for sleeping, the only excep-
tion is sexual activity. 
- Only go to bed when you are drowsy and expect 
to fall asleep immediately. 
- If no sleep occurs after about 15 minutes, the bed 
should be left again. 
- Non-stimulating activities can be performed after 
leaving the bed 
- The bed is only visited again when there is drows-
iness and immediate falling asleep is to be ex-
pected. 
- If sleep does not return after about 15 minutes, the 
bed should be left again. 
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- This cycle is repeated as often as necessary. 
- The time to get up in the morning is determined 
and adhered to. 
- Sleep during the day should be avoided 
Stimulus control has also been shown to be very 
effective in the elderly (Cochen et al., 2009), but 
often meets its limits in this patient group. For ex-
ample, the requirement to leave the bed is per-
ceived as too annoying and is therefore often omit-
ted. Similarly, immobility, pain or muscle weak-
ness often make it impossible to leave the bed de-
spite the patient's willingness to do so.  
Due to these practical problems, the method has 
been modified with the counter-control method that 
also allows less mobile patients to apply these prin-
ciples (Spira et al., 2016). Instead of getting up, 
patients are encouraged to free themselves mentally 
from the compulsion to want to sleep and, in case 
of insomnia, to sit up and read, listen to music or 
watch TV until they are expected to immediately 
fall asleep again. This modified procedure has 
proven to be effective, but did not achieve the ef-
fectiveness of the actual stimulus control. There-
fore, this modification should only be applied to 
patients who are unable to get out of bed especially 
for the residents in retirement homes. 
Sleep Restriction 
According to the rules of Sleep Restriction, the time 
spent in bed should be equal to the average esti-
mated sleep time (Spielmann 1987). Thus, the 
sleep pressure increases within the restricted time in 
bed which leads to a better quality of sleep. But in 
reality, the rigid and for younger people, very effec-
tive method cannot be used in such a rigid format 
for elderly residents in retirement homes. 
Therefore, the method of sleep compression can be 
implemented so that the total time spent in bed is 
reduced on a weekly basis for 20-30 minutes. 
Within several weeks, the time in bed will almost 
reach the average sleep time with a sleep efficiency 
of over 85% (Kenneth et al. 1988). 
Light therapy  
The brightness of the environment plays a funda-
mental role in the regulation of the circadian 
rhythm. Therefore, light plays an important role in 
the treatment of sleep disorders (McCurry et al., 
2011). Light plays an important role in stabilising 
the day-night rhythm. Bright daylight is one of the 
most important timers. Sufficient exposure to light 
during the day increases the amplitude of the circa-
dian rhythm and stabilises the phase. The time and 
intensity of light exposure play an important role 
(Figueiro, 2017; Richter et al. 2014).  
Already dark rooms in the afternoon, no light ex-
posure during the day, brightly lit rooms for care at 
night, bright illumination when going to the toilet, 
the nocturnal use of smartphones or watching tele-
vision at night are negative examples of how sleep 
can be disturbed by light exposure. Recognising 
this and applying this knowledge in everyday life is 
a sustainable measure to improve the sleep of older 
individuals. 
Although the results of therapy studies on the effect 
of light therapy in people with Alzheimer's demen-
tia are predominantly contradictory for methodo-
logical reasons, overall positive effects tend to 
emerge. In one study, for example, people with 
Alzheimer's disease experienced an improvement 
of seasonal mood swings under light therapy 
(Hickman et al., 2007). Therefore, light therapy is a 
therapeutic option for people with dementia and 
circadian rhythm disorders, especially due to its 
low side-effect rate (Richter, Myllymaeki et al., 
2014). 
The efficacy of light therapy is well documented 
for exposure of 10,000 lux for half an hour or 2,500 
lux for two hours (Schneider, Härter & Schorr, 
2017). Light therapy can be applied in various 
forms. The decisive factors are the intensity, timing 
and duration of application. The simplest form of 
light therapy is to go outdoors.  
If an artificial light source is used, the patient should 
not sit more than 50-80 cm away from it. It is vital 
that the light falls on the retina. Therefore, the eyes 
must be open and must not be covered by sun-
glasses for example. However, the patient should 
not look directly into the light source. 
Alternatively, a light box can be used, which is set 
approximately one metre away from the patient, or 
lights can be installed in the ceiling. It is better to 
integrate lighting systems into a communal room. 
This allows light therapy to be applied simultane-
ously with other activities. This sustainably pro-
motes compliance (Bloom et al., 2009).  
Using a combination of methods including Ele-
ments of CBT-I, Light Therapy and physical activi-
ty can also improve the depressive mood in elderly 
individuals with chronic insomnia and depression 
(Richter et al. 2018) 
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Digital treatment of Insomnia 
In the course of the digitalisation and virtualisation 
of therapeutic measures in the field of insomnia 
through virtual coaches (Peter et al. 2019), online 
treatment and online-guided interventions, the 
effectiveness of such measures must also be exam-
ined here. A systematic literature review in which 
numerous studies on the insomnia treatment of 
older persons by new communication technologies 
were examined shows that sleep quality can be 
improved (Salvemini et al., 2019). This is also 
important because the availability of behavioural 
intervention methods for the elderly is still too lim-
ited.  
Medications for the treatment of Insomnia 
In the elderly, benzodiazepines and benzodiazepin 
receptor agonists are equally effective for short-
term treatment.   
Almorexant as an dual orexin receptor and Su-
vorexant as an orexin receptor antagonist and an-
tagonist approved for treating insomnia at doses of 
10-20 mg which generally improves sleep mainte-
nance and onset over 3 months are both well-
tolerated in elderly patients with insomnia (Herring 
et al. 2017, Roth et al.2017).  
The range of medications for the treatment of in-
somnia is broad. The clinical decision for a particu-
lar drug depends on the type of treatment: 
- from the period of time until the maximum effec-
tive level is reached 
- the half-life of the preparation 
- the binding behaviour of the preparation to recep-
tors 
- the metabolism of the preparation 
The time it takes to reach the maximum effective 
level determines when a medication should be 
taken and whether it can be used as a sleeping pill 
or as a sleeping through pill. If, for example, the 
maximum effect level is reached after more than 
two hours, such a preparation is less suitable as a 
sleeping pill. 
The half-life of a drug, on the other hand, allows 
the duration of effectiveness to be estimated and 
possible transition phenomena to be anticipated. 
Such relationships between pharmacokinetics and 
pharmacodynamics are well established for benzo-
diazepines and Z-substances. For other substances, 
the relationship is more complex. For doxepin, for 
example, the maximum clinical effect occurs sev-
eral hours after reaching the maximum serum level 
(Hajak, 2001). 
The binding profile of the hypnotics to the various 
receptors is responsible for their effect, but also for 
their side effects. Table 1 shows a selection of sub-
stances with sedative properties and their effect 
profile on the various receptors. 
Knowledge of receptor occupation is important for 
these preparations, as it provides information on the 
expected side effect profile. Binding to benzodiaz-
epine receptors shows a dose-response relationship 
with effects such as sedation, but also dizziness, 
forgetfulness, ataxia and dependence (Bent, Padula, 
Moore, Patterson & Mehling, 2006). The unde-
sired effects are less pronounced with the so-called 
Z-substances, but are also present. 
Anticholinergic effects are xerostomia, dizziness, 
constipation, accommodation disorders and urinary 
retention. The drugs that show these adverse effects 
include tricyclic antidepressants, but also the over-
the-counter drugs diphenhydramine and doxyla-
mine. It is interesting in this context that doxepin in 
a low dosage of 3 mg is approved as a hypnotic in 
the USA and shows practically no anticholinergic 
effects (Krystal et al., 2010). 
A blockade of the histamine H1 receptor causes 
sedation. Examples of this effect are the prepara-
tions doxepin, amitriptyline, mirtazapine, quetiap-
ine, diphenhydramine blocking have among others 
amitriptyline, doxepin, trazodone, quetiapine, 
olanzapine and risperidone. The atypical neurolep-
tics risperidone, olanzapine and quetiapine have a 
dose-dependent blocking effect on the dopamine 
receptor. Clinically, this blockade causes- albeit 
rarely - extrapyramidal movement disorders such 
as tardive dyskinesia or akathisia. All of these ad-
verse effects are dose-dependent. Therefore, it is 
recommended to start with the lowest possible dose 
and slowly increase it while monitoring the effects 
and side effects (Reinbold & Assion, 2009).  
The type of metabolism of the respective substanc-
es is particularly relevant in the context of the 
polypharmacy of older people. High serum levels 
can be produced and undesirable effects can occur 
as a result of the over division of degradation path-
ways between different substances. 
Randomised and placebo-controlled studies of 
hypnotics are essential to assess the efficacy and 
potency of medications. In these studies - discrep-
ant to the clinical reality of demand - predominant-
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ly middle-aged people and rarely seniors (65+) 
were examined. In summary, the changes in sleep 
latency and nocturnal wakefulness obtained by 
means of self-assessment (sleep diary) or meas-
urement in the sleep laboratory by hypnotics are in 
the range of 10 to 30 minutes. These values are 
sobering. However, it must always be taken into 
account that the significance of such an improve-
ment can already mean a relevant improvement for 
the individual patient, which increases his quality of 
life. Therefore, the therapeutic effect of hypnotic 
therapy cannot be assessed solely on the basis of 
objective parameters (Kaufmann, Spira, Alexan-
der, Rutkow & Mojtabai, 2016). Herbal prepara-
tions also show positive effects when evaluated by 
the patient, even if no significant differences can be 
demonstrated with objective procedures compared 
to a placebo (Bent et al., 2006; Glass, Sproule, 
Herrmann, Streiner & Busto, 2005). 
Antihistamines, antipsychotics and antidepressant 
medication which can have anticholinergic side 
effects should be carefully considered. Low doses 
of Doxepin in doses from 3 to 6 mg per day could 
be a feasible treatment option (Fraase et al. 2019, 
Hertenstein et al. 2017)   
Table 1  
Drug groups and their effects on individual sleep parameters 
Drug group SL TST REM WASO N1/N2 N3 OSAS PLMS 
BZD ↓ ↑ ↓ ↓ ↑ ↓ ↑  
Z-Substances ↓ ↑  ↓     
Antihistamines ↓  ↓      
Melatonin ↓   ↓     
Alcohol ↓  ↓ ↑  ↑ ↑  
Table 2 
Antidepressants and their effects on individual sleep parameters (according to Riemann et al. 2019) 
Drug group Sleep contiunity  Slow wave sleep  REM sleep  
TCA ↑ ↑  ↓ 
SSRI ↓ ? ↓ 
Trimipramin ↑   
Trazodon ↑ ↑  
Mirtazapin ↑   
SL: Sleep latency, TST: Total Sleep Time, REM: paradox sleep (with rapid eye movements), WASO: Wake 
Time After Sleep Onset, N1/N2: Light sleep, N3: slow wave sleep, OSAS: obstructive sleep apnea syndrome, 
PLMS: periodic limb movements of sleep, BZD: benzodiazepines, Z substances: Non-benzodiazepine ago-
nists, TCA: tricyclic antidepressants, SSRI: selective serotonin reuptake inhibitors (antidepressants), ↑: in-
creased/amplified, ↓ reduced.              : no changes 
When treating Insomnia with medication, seven 
essential points should be considered (Reinbold & 
Assion, 2009). 
- prescribe the lowest effective dose 
- intermittent use (2-4x per week) 
- use for a short period of time (3-4 weeks) 
- gradual termination of therapy to avoid rebound 
insomnia  
- prescription of drugs with short half-lives 
- proof the interaction with other drugs 
- be aware of the anticholinergic effects 
The selection of the medication should be based on 
the presence and the extent of the impaired daily 
well-being, and also possible effects on various 
sleep parameters as listed in Table 1 should be 
taken into account. Most of the drugs presented in 
Table 2 are off-label, but still used on a daily basis. 
The expected effect should improve sleep and 
well-being during the day. It is particularly im-
portant to agree on a time-limited and intermittent 
prescription with the patient at an early stage so that 
pharmacotherapy can be discontinued after the 
treatment phase (Reinbold & Assion, 2009). Such 
an agreement made in advance before the start of 
therapy reduces the probability of long-term use 
and abuse. 
The indication for drug treatment of insomnia is 
given when the disorder is severe and a treatment 
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period of two to four weeks is planned. The lowest 
possible dose should always be chosen. 
The strength of the effect of the most frequently 
prescribed hypnotics - benzodiazepines and Z-
substances - on subjective sleep quality is moder-
ate. The assessment of the effects of benzodiaze-
pines in elderly people is further complicated by the 
fact that the studies on their efficacy often included 
only a few patients, who were also selected by 
rigorous inclusion and exclusion criteria. There are 
no long-term studies on the efficacy of hypnotics in 
the elderly. 
In light of the currently available data, it is still not 
possible to make a reliable estimate of how long 
pharmacological treatment of Insomnia is required. 
Nonetheless, the necessity of the continuation of 
therapy with hypnotics should always be discussed 
with the patient. If a slow reduction of the dose 
does not lead to a recurrence of the symptoms, a 
therapy with hypnotics that has been discontinued 
once should not be started again. However, if the 
initial symptoms reappear or the patient's quality of 
life deteriorates, a resumption of the therapy should 
be considered. 
Conclusion 
In conclusion, the cognitive behavioural therapy for 
insomnia (CBT I) of Insomnia is also the interven-
tion of choice for older people according to the 
guidelines (Riemann, Baum et al., 2017, Riemann, 
Baglionni et al. 2017, AASM 2014). However, the 
patient must be aware that the desired effect is not 
immediate when applying behavioural measures 
and that there are some limitations and obstacles for 
the implementation of stimulus control and sleep 
restriction in elderly individuals and residents in 
retirement homes. Stimulus control can be modi-
fied to allow the elderly and often multi-morbid 
patients to stay in their bed in a sitting position to 
avoid falling in the night. The sleep restriction may 
be modified into sleep compression. Light Therapy 
can complete the non-pharmacological measures. 
Pharmacological measures should be the second 
and last choice of treatment considering that their 
benefit in long-term use is very restricted and can 
lead to dependency, falling during the night and to 
a worsening of the cognition. They should only be 
used in the short term to reduce distress and should 
be integrated into an overall therapeutic concept. 
Anyway, because of their potential for tolerance 
and dependence especially in the elderly, they are 
only recommended for a treatment period up to 
four weeks. Low doses of sedating antidepressants 
are commonly prescribed for treating chronic in-
somnia and have shown promising results in clini-
cal trials. Melatonin and ramelteon can be more 
efficacious in elderly patients. Antihistamines, 
antipsychotics and antidepressant medication can 
cause anticholinergic side effects and should be 
administrated  carefully and in low doses.   
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